This single-center observational study compared the outcomes of transcarotid transcatheter aortic valve implantation (TC-TAVI) with those of conventional surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis who were not suitable candidates for transfemoral access.

A recent study compared outcomes of transcatheter edge-to-edge repair (Abbott MitraClip®) versus surgical mitral repair in octogenarian patients with severe organic mitral regurgitation, aiming to evaluate safety, efficacy, and midterm outcomes

A new U.S. study analyzes outcomes of transcatheter aortic valve implantation (TAVI) versus conventional surgical aortic valve replacement (SAVR) in patients younger than 65 years, highlighting the growing expansion of TAVI despite limited evidence on long-term durability.

The 2025 ESC/EACTS update redefines the boundaries between surgery and transcatheter therapy. It advocates earlier intervention in severe aortic stenosis, lowers the age threshold for TAVI to 70 years, expands the use of MitraClip to lower-risk scenarios, promotes percutaneous tricuspid treatment, and grants a new central role to advanced imaging in decision-making.